BRIEF: Duality Biotherapies surges in Hong Kong trading debut

9606.HK

Shares of biotech firm Duality Biotherapeutics Inc. (9606.HK) opened up 91% at HK$181 on Tuesday and continued to climb in their Hong Kong trading debut, closing up 127% at HK$214.80 by the midday break.

The company said it sold 17.33 million shares priced at HK$ 94.60 each, representing the bottom of their range, raising net proceeds of HK$ 1.51 billion ($195 million). The Hong Kong portion of the share sale was oversubscribed by 114 times, while the international tranche was 12.5 times oversubscribed.

Duality reported 2024 revenue of 1.94 billion yuan, up 8.7% year-over-year, while its net loss nearly tripled to 1.05 billion yuan.

The company plans to use 45% of proceeds from the listing for R&D and commercialization of its core products, DB1303 and DB-1311. It will use 30% for R&D of other key products, and 15% for continued development of its ADC technology platform.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, click here

,
, ,

Related Articles

RELATED ARTICLES

  1. BRIEF: Mixue surges on Hong Kong trading debut
    2097.HK
  2. BRIEF: Mao Geping surges in Hong Kong trading debut
    1318.HK
  3. After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
    2696.HK
  4. BRIEF:Bloks surges in Hong Kong trading debut
    0325.HK
  5. BRIEF: Herbs Generation surges in Hong Kong trading debut
    2593.HK
  6. X.J. Electrics cooks up Hong Kong IPO, hoping to follow Carote’s hot debut
  7. BRIEF: Chifeng Gold opens flat in Hong Kong trading debut
    6693.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Illustration of the rebound of Chinese fintech lenders

A fintech lender rebound, and a hotel mess

Fintech lenders are entering a new golden era, with Jiayin reporting 46% growth for its core consumer lending business in last year's fourth quarter and forecasting similar gains this year. What's driving this rebound? And hotelier H World is still trying to fix a German acquisition from 2019 that wiped out its profit in the fourth quarter of last year. Will the Chinese hotelier be able to turn around this money-losing offshore asset?
JFIN.US HTHT.US